Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

107.60USD
3:59pm EST
Change (% chg)

$-0.45 (-0.42%)
Prev Close
$108.05
Open
$108.25
Day's High
$108.50
Day's Low
$107.10
Volume
655,340
Avg. Vol
610,002
52-wk High
$149.17
52-wk Low
$96.18

Select another date:

Mon, Nov 6 2017

BRIEF-Alexion receives new Japanese patent for Soliris

* Alexion receives new Japanese patent for Soliris® (eculizumab), extending patent protection into 2027 and strengthening global patent portfolio Source text for Eikon: Further company coverage:

BRIEF-Alexion reports Q3 non-GAAP earnings per share of $1.44

* Q3 earnings per share view $1.32 -- Thomson Reuters I/B/E/S

RPT-BRIEF-Alexion announces interim analysis from phase 3 open-label extension study of Soliris

* Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis

BRIEF-Interim analysis from phase 3 open-label extension study of Soliris

* Interim analysis from phase 3 open-label extension study shows sustained benefits of Soliris (Eculizumab) treatment for patients with refractory generalized myasthenia gravis

Alexion Pharma to lay off 20 percent of workforce

Alexion Pharmaceuticals Inc said on Tuesday it would lay off about 20 percent of its workforce and sharpen its focus on its core rare disease drugs business, as it looks to restore investor confidence.

UPDATE 2-Alexion Pharma to lay off 20 pct of workforce

* Drugmaker's shares down slightly (Adds details, analyst comment, updates share price)

Drugmaker Alexion to cut 20 pct of jobs

Sept 12 U.S. drugmaker Alexion Pharmaceuticals Inc said on Tuesday it would lay off about 20 percent of its global workforce in an effort to cut spending.

BRIEF-Alexion to reduce 20 pct of its global workforce

* Alexion announces restructuring to advance corporate strategy

BRIEF-Alexion receives three U.S. Patents for Soliris (eculizumab), extending patent protection into 2027

* Alexion receives three U.S. Patents for Soliris (eculizumab), extending patent protection into 2027

BRIEF-Third Point LLC takes share stake in Blackrock Inc, Alexion Pharmaceuticals

* Third Point LLC takes share stake of 1.6 million shares in Blackrock Inc - SEC filing‍​

Select another date: